Edaravone of Mitsubishi Tanabe was approved for marketing in China on July 31, 2019, with the acceptance No.: JXHS1900047 and indication of amyotrophic lateral sclerosis (ALS). The drug was included in the list of 2nd batch of clinically imperative overseas new drugs and was directly filed the marketing application to the NMPA on Apr. 12, 2019
